The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: Generation of chimeric receptors with a novel ligand-selective profile

Journal of Neurochemistry

Volumn 73, Issue 2, 1999, Pages 821-829

  Dautzenberg, Frank M ^a   Kilpatrick, Gavin J ^a   Wille, Sandra ^c   Hauger, Richard L ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Chimeric receptor construction; Cyclic AMP; Ligand binding; Mutagenesis

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR; RECEPTOR SUBTYPE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; LIGAND BINDING; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT; RECEPTOR AFFINITY; RECEPTOR BINDING; SHEEP; XENOPUS;

ANIMALS; BINDING, COMPETITIVE; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; EXTRACELLULAR SPACE; HUMANS; IODINE RADIOISOTOPES; KIDNEY; LIGANDS; MOLECULAR SEQUENCE DATA; MUTAGENESIS; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RADIOLIGAND ASSAY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECOMBINANT FUSION PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; TRANSFECTION; VASODILATOR AGENTS; XENOPUS;

ANIMALIA; OVIS; OVIS ARIES;

EID: 0032810498     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0730821.x     Document Type: Article

References (37)

1. Arborelius L., Owens M. J., Plotsky P. M., and Nemeroff C. B. (1999) The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160, 1-12.
2. 2 α and β splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay. Neuropharmacology 38, 441-448.
3. Cascieri M. A., Fong T. M., and Strader C. D. (1997) Molecular characterization of a common binding site for small molecules within the transmembrane domain of G-protein coupled receptors. J. Pharmacol. Toxicol. Methods 33, 179-185.
4. Chalmers D. T., Lovenberg T. W., Grigoriadis D. E., Behan D. P., and De Souza E. B. (1996) Corticotropin-releasing factor receptors: from molecular biology to drug design. Trends Pharmacol. Sci. 17, 166-172.
5. 1 receptor: three nonadjacent amino acids are responsible for species selectivity with respect to recognition of peptide histidine isoleucineamide. J. Biol. Chem. 271, 12795-12800.
6. Dautzenberg F. M., Dietrich K., Palchaudhuri M. R., and Spiess J. (1997) Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor. J. Neurochem. 69, 1640-1649.
7. Dautzenberg F. M., Wille S., Lohmann R., and Spiess J. (1998) Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site. Proc. Natl. Acad. Sci. USA 95, 4941-4945.
8. DeAlmeida V. I. and Mayo K. E. (1998) Identification of binding domains of the growth hormone-releasing hormone receptor by analysis of mutant and chimeric receptor proteins. Mol. Endocrinol. 12, 750-765.
9. Dieterich K. D., Lehnert H., and De Souza E. B. (1997) Corticotropin-releasing factor receptors: an overview. Exp. Clin. Endocrinol. Diabet. 105, 65-82.
10. Donaldson C., Sutton S., Perrin M. H., Corrigan A. Z., Lewis K. A., Rivier J., Vaughan J. M., and Vale W. W. (1996) Cloning and characterization of human urocortin. Endocrinology 137, 2167-2170.
11. Dunn A. J. and Berridge C. W. (1990) Physiological and behavioral responses of corticotropin releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15, 71-100.
12. 3H]-urocortin. Neuropharmacology 36, 1439-1446.
13. Gourlet P., Vilardaga J. P., de Neef P., Waelbroeck M., Vandermeers A., and Robberecht P. (1996) The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 17, 825-829.
14. Hashimoto H., Ogawa N., Hagihara N., Yamamoto K., Imanishi K., Nogi H., Nishino A., Fujita T., Matsuda T., Nagata S., and Baba A. (1997) Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide receptor chimeras reveal domains that determine specificity of vasoactive intestinal polypeptide binding and activation. Mol. Pharmacol. 52, 128-135.
15. Hauger R. L., Dautzenberg F. M., Flaccus A., Liepold T., and Speiss J. (1997) Regulation of corticotropin-releasing factor receptor function in human Y-79 retinoblastoma cells: rapid and reversible homologous desensitization but prolonged recovery. J. Neurochem. 68, 2308-2316.
16. Holtmann M. H., Hadac E. M., and Miller L. J. (1995) Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. J. Biol. Chem. 270, 14394-14398.
17. Holtmann M. H., Ganguli S., Hadac E. M., Dolu V., and Miller L. J. (1996) Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor. J. Biol. Chem. 271, 14944-14949.
18. Ishihara T., Nakamura S., Kaziro Y., Takahashi T., Takahashi K., and Nagata S. (1991) Molecular cloning and expression of a cDNA encoding the secretin receptor. EMBO J. 10, 1635-1641.
19. Ishihara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8, 811-819.
20. 2γ receptor. Mol. Endocrinol. 12, 1077-1085.
21. Lederis K., Letter A., McMaster D., and Moore G. (1982) Complete amino acid sequence of urotensin-I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Science 218, 162-164.
22. Lee C. W., Luck M. D., Jüppner H., Potts J. T. Jr., Kronenberg H. M., and Gardella T. J. (1995) Homolog-scanning mutagenesis of the parathyroid hormone (PTH) receptor PTH-(1-34) binding determinants in the third extracellular loop. Mol. Endocrinol. 9, 1269-1278.
23. Liaw C. W., Lovenberg T. W., Barry G., Oltersdorf T., Grigoriadis D. E., and De Souza E. B. (1996) Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid. Endocrinology 137, 72-77.
24. Liaw C. W., Grigoriadis D. E., Lovenberg T. W., De Souza E. B., and Maki R. A. (1997a) Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach. Mol. Endocrinol. 11, 980-985.
25. Liaw C. W., Grigoriadis D. E., Lorang M. T., De Souza E. B., and Maki R. A. (1997b) Localization of agonist- and antagonist-binding domains of human corticotropin releasing factor receptors. Mol. Endocrinol. 11, 2048-2053.
26. Lin H. Y., Harris T. L., Flannery M. S., Aruffo A., Kaji E. H., Gorn A., Kolakowski L. F. Jr., Lodish H. F., and Goldring S. R. (1991) Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254, 1022-1024.
27. Mayo K. E. (1992) Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol. Endocrinol. 6, 1734-1744.
28. Montecucchi P. C. and Henschen A. (1981) Amino acid composition and sequence analysis of sauvagine, a new active peptide from the skin of Phyllomedusa sauvagei. Int. J. Pept. Prot. Res 18, 113-120.
29. Munson P. J. and Rodbard D. (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107, 220-239.
30. Nicole P., Du K., Couvineau A., and Laburthe M. (1998) Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship. J. Pharmacol. Exp. Ther. 284, 744-750.
31. Palchaudhuri M. R., Wille S., Mevenkamp G., Speiss J., Fuchs E., and Dautzenberg F. M. (1998) Corticotropin-releasing factor receptor type 1 from Tupaia belangen: cloning, functional expression and tissue distribution. Eur. J. Biochem. 258, 78-84.
32. Palchaudhuri M. R., Hauger R. L., Wille S., Fuchs E., and Dautzenberg F. M. (1999) Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangen. J. Neuroendocrinol. 11, 419-428.
33. Perrin M. H., Sutton S., Bain D., Berggren W. T., and Vale W. W. (1998) The first extracellular domain of corticotropin-releasing factor-Rl contains major binding determinants for urocortin and astressin. Endocrinology 139, 566-570.
34. Svoboda M., Tastenoy M., Van Rampelbergh J., Goossens J. F., De Neef P., Waelbroeck M., and Robberecht P. (1994) Molecular cloning and functional characterization of a human VIP receptor from SUP-T1 lymphoblasts. Biochem. Biophys. Res. Commun. 205, 1617-1624.
35. Valdenaire O., Giller T., Breu V., Gottowick J., and Kilpatrick G. (1997) A new functional isoform of the human CRF2 receptor for corticotropin-releasing factor. Biochim. Biophys. Acta 1352, 129-132.
36. Vaughan J., Donaldson C., Bittencourt J., Perrin M. H., Lewis K., Sutton S., Chan R., Turnbull A. V., Lovejoy D., Rivier C., Rivier J., Sawchenko P. E., and Vale W. (1995) Urocortin, a mamalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378, 287-292.
37. Wille S., Sydow S., Palchaudhuri M. R., Speiss J., and Dautzenberg F. M. (1999) Identification of amino acids in the N-terminal domain of corticotropin-releasing factor receptor 1 that are important determinants of high affinity ligand binding. J. Neurochem. 72, 388-395.